Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why combination treatment is common Many people living with type 2 diabetes require more than one medicine to manage blo

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different medicines Although both Wegovy and Contrave are used for weight management, they belong to very different drug families and work in different ways. Wegovy contains semaglutide, a GLP-1 recepto

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type 2 diabetes. Weight changes with dulaglutide are usually modest compared with the significant reductions seen in trials of semaglutide for obesity. Different active ingredients and purposes The first key difference is that Wegovy and Trulicity contain different GLP-1 receptor agonists. Wegovy delivers semaglutide at doses up to 2.4 mg weekly,

Use once weekly, same day each week, with or without food, alongside a reduced-calorie eating plan and regular activity. Keep hydrated,...

Standard UK instructions start at 0.25 mg once weekly and step up gradually to improve comfort and reduce tummy side effects. Starting at 0.5 mg is not the routine plan and tends to increase nausea for first-time GLP-1 users. If you’ve previously tolerated a GLP-1, your prescriber will still weigh the pros and cons before deviating from the usual start. Why titration matters Wegovy contains semaglutide, a GLP-1 receptor agonist that acts on appetite control centres in the bra

You can change your weekly injection day if needed, as long as there are at least 3 days (72 hours) between two doses. After switching, keep to the new weekly day going forward. For missed doses, the rule is different: if you are within 5 days, take it as soon as you remember; if it has been more than 5 days, skip it and take the next dose on your usual day. Why flexibility is built in Wegovy is prescribed as a once-weekly injection. The idea is to give people a medicine that

Yes — official tutorial videos exist and are helpful, but they don’t replace the patient leaflet or nurse/pharmacist teaching. Ask your clinic to point you to their preferred video and walk you through the device steps. If anything in the video differs from your pen’s instructions, follow your pen’s leaflet. Why videos can help Learning an injection technique is easier when you see it done. A clear video shows hand position, pen angle, and the pace at which the button is pres

Check your dose strength, attach a new needle, and follow the step-by-step device guide (including the brief “flow check” where shown)....

Recommended sites are the abdomen, thigh, or upper arm. Rotate sites each week to reduce local irritation, and avoid areas that are tender, bruised, scarred, or inflamed. If a spot stings or looks red after, switch to a different area next time and mention it at your review. NHS training stresses that choosing the right location improves comfort and consistency over the long term. Why injection site matters Wegovy is given subcutaneously, meaning the medicine needs to sit in

Wegovy has been tested in large clinical trials and shown to deliver sustained, clinically meaningful weight loss. Over-the-counter supplements rarely have robust evidence and typically produce little to no lasting effect, so the gap in proven effectiveness is significant. What makes Wegovy different Wegovy contains semaglutide, a GLP-1 receptor agonist that has been through rigorous clinical trials involving thousands of participants worldwide. The STEP programme of studies

Many people on Wegovy report fewer food cravings and better control over eating, which can reduce stress around meals. Other drugs like Mysimba may also affect mood and cravings, but semaglutide’s impact on appetite tends to have the strongest indirect psychological benefit. Why psychological effects matter Weight management is never only about the body. Emotional wellbeing, self-confidence, and the stress of managing food choices all play a big role in how people experience

Clinical trials included adults up to their mid-70s, and weight loss benefits were seen across age groups. There’s limited evidence directly comparing older versus younger adults, but no major differences in effectiveness have been noted, though older people may be more sensitive to side effects. Who was included in the trials The large clinical trials of semaglutide, such as the STEP programme, included adults with overweight or obesity up to about 75 years old. This means w

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and Orlistat, by contrast, are small-molecule tablets made by chemical synthesis. These differences influence regulation and supply but not day-to-day use for patients. What makes Wegovy a biologic Wegovy (semaglutide) belongs to a group of medicines known as biologics. These are typically large, complex molecules produced in living cells using r

Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for diabetes at lower doses, while Wegovy provides the same benefits at higher doses alongside more pronounced weight reduction. How semaglutide works on blood sugar Semaglutide, the active ingredient in both Wegovy and Ozempic, belongs to the GLP-1 receptor agonist family. It lowers blood sugar by stimulating insulin release when glucose level

Yes — trials show Wegovy users lose more weight earlier than with Saxenda, thanks to its stronger appetite effect and weekly dosing. That said, both require steady use over months for results to build. The two medicines at a glance Wegovy and Saxenda belong to the same family of medicines, GLP-1 receptor agonists. They help people feel fuller sooner, reduce appetite, and support healthier eating. The difference lies in the active ingredient and how they are dosed: Wegovy cont

In many cases, Wegovy can be used as the main weight loss medicine, especially when diet and exercise alone haven’t worked. However, switching or replacing other drugs should always be guided by a clinician, as some combinations may still be appropriate depending on health needs. Wegovy as a first-choice option Since its approval by NICE in 2023, Wegovy (semaglutide 2.4 mg weekly) has become the leading option for medical weight management in the UK. Clinical evidence from th

Wegovy mimics the hormone GLP-1, acting on the brain to reduce appetite and slow digestion. Contrave (naltrexone/bupropion) affects brain reward and craving pathways, which can reduce emotional eating but doesn’t directly target satiety hormones. How Wegovy works Wegovy (semaglutide 2.4 mg weekly) is a GLP-1 receptor agonist. It mimics a natural gut hormone called GLP-1, which signals to the brain that you are full, slows down stomach emptying, and enhances insulin release wh

Both Wegovy (semaglutide 2.4 mg) and Trulicity (dulaglutide) improve blood sugar, but semaglutide generally produces greater reductions in HbA1c and body weight. NICE recommends semaglutide more widely for people needing weight-focused management. Two GLP-1 medicines, one key difference Wegovy and Trulicity both belong to the GLP-1 receptor agonist family of medicines. They mimic the hormone GLP-1, which reduces appetite, slows digestion, and stimulates insulin release when b

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve outcomes. Other drugs may be chosen if semaglutide is unsuitable, but few have shown the same range of benefits across multiple health conditions. Why certain conditions matter Weight-related health problems often go beyond the number on the scales. People with obesity are more likely to develop type 2 diabetes, cardiovascular disease, and sl